The effects of intravenous TRH administration on brown adipose tissue activity in healthy, lean men.

The effects of intravenous TRH administration on brown adipose tissue activity in healthy, lean men. - BATman-study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON41582

Enrollment

Registered

2014-04-15

Start date

2014-06-05

Completion date

Unknown

Last updated

2025-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesitas Obesity

Interventions

Intravenous TRH administration.

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Male sex Age between 30 and 50 years old BMI range 19 to 25 kg/m2

Exclusion criteria

Exclusion criteria: Treated or untreated hypo- or hyperthyroidism Renal dysfunction (eGFR >60) Use of any medication known to affect thyroid hormone metabolism or the autonomic nervous system Any cardiovascular disease Recent stay of >2 weeks in the tropics within the last 6 weeks The desire to conceive within 1 month

Design outcomes

Primary

Measure	Time frame
The degree of 18F-FDG uptake in BAT, skin temperature, blood pressure, heart rate, and serum TSH, T3, T4, FT4, norepinephrine and normetanephrine after TRH administration, compared to saline administration;	—

Secondary

Measure	Time frame
The association between BAT acitvity and changes in blood pressure, heart rate, and serum TSH, T3, T4, FT4, norepinephrine and normetanephrine.	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)